"Double-Blind Method" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
| Descriptor ID |
D004311
|
| MeSH Number(s) |
E05.318.780.300 E05.581.500.300 N05.715.360.780.320 N06.850.520.445.300
|
| Concept/Terms |
Double-Blind Method- Double-Blind Method
- Double Blind Method
- Double-Blind Methods
- Method, Double-Blind
- Methods, Double-Blind
- Double-Masked Method
- Double Masked Method
- Double-Masked Methods
- Method, Double-Masked
- Methods, Double-Masked
- Double-Masked Study
- Double Masked Study
- Double-Masked Studies
- Studies, Double-Masked
- Study, Double-Masked
- Double-Blind Study
- Double Blind Study
- Double-Blind Studies
- Studies, Double-Blind
- Study, Double-Blind
|
Below are MeSH descriptors whose meaning is more general than "Double-Blind Method".
Below are MeSH descriptors whose meaning is more specific than "Double-Blind Method".
This graph shows the total number of publications written about "Double-Blind Method" by people in this website by year, and whether "Double-Blind Method" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 17 | 17 |
| 1996 | 0 | 17 | 17 |
| 1997 | 0 | 29 | 29 |
| 1998 | 0 | 13 | 13 |
| 1999 | 0 | 22 | 22 |
| 2000 | 0 | 22 | 22 |
| 2001 | 0 | 19 | 19 |
| 2002 | 0 | 32 | 32 |
| 2003 | 0 | 30 | 30 |
| 2004 | 0 | 35 | 35 |
| 2005 | 0 | 40 | 40 |
| 2006 | 0 | 37 | 37 |
| 2007 | 0 | 32 | 32 |
| 2008 | 0 | 41 | 41 |
| 2009 | 0 | 58 | 58 |
| 2010 | 0 | 37 | 37 |
| 2011 | 0 | 61 | 61 |
| 2012 | 0 | 54 | 54 |
| 2013 | 0 | 51 | 51 |
| 2014 | 0 | 82 | 82 |
| 2015 | 0 | 62 | 62 |
| 2016 | 0 | 44 | 44 |
| 2017 | 0 | 70 | 70 |
| 2018 | 0 | 65 | 65 |
| 2019 | 0 | 56 | 56 |
| 2020 | 0 | 54 | 54 |
| 2021 | 0 | 53 | 53 |
| 2022 | 0 | 47 | 47 |
| 2023 | 0 | 41 | 41 |
| 2024 | 0 | 49 | 49 |
| 2025 | 0 | 38 | 38 |
To return to the timeline,
click here.
Below are the most recent publications written about "Double-Blind Method" by people in Profiles.
-
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
-
Revisiting the Effect of Udenafil on Exercise Performance in Patients With Fontan Circulation: Results of a Post Hoc Analysis of the FUEL Trial. J Am Heart Assoc. 2025 Aug 19; 14(16):e041348.
-
A Phase 2 Randomized Trial of NBI-1065846 (TAK-041) in Patients With Anhedonia Associated With Major Depressive Disorder: Results of the TERPSIS Study. J Clin Psychopharmacol. 2025 Sep-Oct 01; 45(5):432-440.
-
Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics. Am Heart J. 2025 Dec; 290:325-338.
-
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025 Aug; 13(8):687-697.
-
Effectiveness of Omega-3 Fatty Acids Versus Placebo in Subjects at Ultra-High Risk for Psychosis: The PURPOSE Randomized Clinical Trial. Schizophr Bull. 2025 Jul 07; 51(4):1082-1091.
-
Evaluation of a monoclonal antibody against respiratory syncytial virus, clesrovimab, in infants and children: Comprehensive rationale and study design for the late-stage clinical trials. Contemp Clin Trials. 2025 Oct; 157:107995.
-
Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomised, double-blind, active-controlled, multicentre study. Lancet Microbe. 2025 Aug; 6(8):101126.
-
Methylprednisolone for Infant Heart Surgery: Subpopulation Analyses of a Randomized Controlled Trial. Crit Care Med. 2025 Jul 01; 53(7):e1470-e1480.
-
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 Jul 03; 393(1):51-61.